Analysts predict that Codexis, Inc. (NASDAQ:CDXS) will announce earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks. Three analysts have made estimates for Codexis’ earnings, with estimates ranging from ($0.07) to ($0.01). The firm is scheduled to announce its next quarterly earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Codexis will report full year earnings of ($0.05) per share for the current year, with EPS estimates ranging from ($0.07) to ($0.03). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.09) to $0.05. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Codexis.
Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The firm had revenue of $12.32 million for the quarter, compared to the consensus estimate of $14.90 million. Codexis had a negative net margin of 23.13% and a negative return on equity of 21.60%.
CDXS has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $22.50 price objective on shares of Codexis in a research report on Thursday, August 8th. BidaskClub downgraded shares of Codexis from a “sell” rating to a “strong sell” rating in a research report on Thursday. Finally, Zacks Investment Research downgraded shares of Codexis from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Codexis has a consensus rating of “Buy” and a consensus target price of $21.58.
Codexis stock traded up $0.08 during mid-day trading on Friday, reaching $13.39. 437,900 shares of the company traded hands, compared to its average volume of 430,326. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.30 and a quick ratio of 6.26. The firm’s 50 day moving average price is $17.57 and its 200 day moving average price is $19.31. The firm has a market capitalization of $776.75 million, a price-to-earnings ratio of -63.76 and a beta of -0.05. Codexis has a 52-week low of $12.81 and a 52-week high of $23.05.
A number of institutional investors have recently modified their holdings of CDXS. Capital Investment Advisory Services LLC purchased a new position in Codexis during the 2nd quarter valued at $37,000. Tower Research Capital LLC TRC purchased a new position in Codexis during the 2nd quarter valued at $41,000. Quantamental Technologies LLC purchased a new stake in shares of Codexis in the 2nd quarter worth about $44,000. Aperio Group LLC purchased a new stake in shares of Codexis in the 2nd quarter worth about $98,000. Finally, Legal & General Group Plc grew its position in shares of Codexis by 12.1% in the 4th quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock worth $157,000 after buying an additional 1,010 shares during the period. 87.27% of the stock is currently owned by institutional investors and hedge funds.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Story: Growth and Income Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.